亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation

医学 加药 彭布罗利珠单抗 中止 药方 回顾性队列研究 内科学 急诊医学 癌症 药理学 免疫疗法
作者
Garth W. Strohbehn,Robert G. Holleman,Jennifer Burns,Mandi L. Klamerus,Michael J. Kelley,Eve A. Kerr,Nithya Ramnath,Timothy P. Hofer
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:8 (11): 1663-1663 被引量:18
标识
DOI:10.1001/jamaoncol.2022.4109
摘要

Extended-interval dosing of pembrolizumab (400 mg every 6 weeks) was approved by US Food and Drug Administration (FDA) in April 2020 as an alternative to standard-interval dosing (200 mg every 3 weeks). Extended-interval dosing may enhance access, alleviate patient and health system financial toxicity, and improve patient quality of life, particularly during the COVID-19 pandemic. Neither adoption nor effectiveness of extended interval in the US has been adequately described.To describe adoption of extended-interval dosing of pembrolizumab since its FDA approval and to measure its preliminary real-world effectiveness compared with standard-interval dosing.This was a retrospective cohort study that used data from the Veterans Health Administration (VHA), a US-based, nationwide single-payer health system. Participants were veterans who were prescribed single-agent pembrolizumab within the VHA between April 1, 2020, and July 1, 2021. Patients receiving combinations of pembrolizumab and cytotoxic chemotherapy or tyrosine kinase inhibitors were excluded. A subcohort of veterans with non-small cell lung cancer (NSCLC) was also identified using claims-based codes.Single-agent pembrolizumab at extended or standard intervals.The number and proportion of single-agent pembrolizumab prescriptions that were extended compared with standard interval. Effectiveness was described in terms of time-to-treatment discontinuation (TTD) and extended- to standard-interval pembrolizumab prescriptions were compared using Cox proportional hazards regression.A total of 835 veterans (mean age [SD], 70.9 [8.7] years; 809 [96.9%] men) began single-agent pembrolizumab during the study period (all-diseases cohort), and of these, 234 (mean [SD] age, 71.6 [7.3] years; 225 [96.2%] men) had NSCLC (NSCLC cohort). Extended-interval adoption reached its steady state plateau of approximately 35% by January 2021; 65% of participants who began standard-interval single-agent pembrolizumab received only standard-interval dosing during the treatment course. In analysis consistent with the intention-to-treat principle, no differences in TTD were observed between standard- and extended-interval dosing in either the all-diseases cohort (HR, 1.00; 95% CI, 1.00-1.00) or the NSCLC cohort (HR, 1.00; 95% CI, 1.00-1.00).This retrospective cohort study found that extended-interval dosing comprised a minority of single-agent pembrolizumab prescriptions despite the FDA approval and its potential health system and public health benefits. The findings support the TTD equivalence of standard- and extended-interval pembrolizumab across indications, complementing clinical pharmacology and single-arm clinical trial data in melanoma. This study provides further support for extended-interval pembrolizumab dosing.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lynn发布了新的文献求助10
2秒前
qin完成签到 ,获得积分10
4秒前
小马甲的应助被奋斗盼海采纳,获得10
10秒前
Lynn完成签到,获得积分10
16秒前
脑洞疼的应助被呵呵采纳,获得10
17秒前
20秒前
奋斗盼海发布了新的文献求助10
24秒前
震动的醉蓝完成签到,获得积分10
25秒前
31秒前
32秒前
Jianing发布了新的文献求助10
37秒前
呵呵发布了新的文献求助10
40秒前
43秒前
李健的小迷弟的应助被渟柠采纳,获得10
49秒前
wanci的应助被科研通管家采纳,获得10
50秒前
1分钟前
渟柠发布了新的文献求助10
1分钟前
urologywang完成签到 ,获得积分10
1分钟前
lili发布了新的文献求助20
1分钟前
淮安石河子完成签到 ,获得积分10
1分钟前
1分钟前
幸福的沛萍完成签到,获得积分10
1分钟前
研友_84mk0L发布了新的文献求助30
1分钟前
1分钟前
默岩1990完成签到,获得积分10
1分钟前
Yalby完成签到,获得积分10
1分钟前
2分钟前
缓慢的映天完成签到,获得积分10
2分钟前
研友_84mk0L发布了新的文献求助10
2分钟前
2分钟前
2分钟前
LTeresa发布了新的文献求助10
2分钟前
Repro发布了新的文献求助10
2分钟前
包容的初阳完成签到,获得积分10
2分钟前
2分钟前
2分钟前
Hello的应助被科研通管家采纳,获得10
2分钟前
研友_84mk0L完成签到,获得积分10
3分钟前
符聪完成签到,获得积分10
3分钟前
Xiaoqiang发布了新的文献求助20
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195122
求助须知:如何正确求助?哪些是违规求助? 9580886
关于积分的说明 21872869
捐赠科研通 7795077
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561228
邀请新用户注册赠送积分活动 2484609